礼来将允许部分患者提前试用实验性减肥药

格隆汇
Aug 04
礼来公司宣布,将允许少数患者在其实验性肥胖症药物retatrutide获得美国FDA批准之前,提前使用该药物。公司发言人表示,对于符合特定医学标准且无法参加临床试验的少数患者,我们认为在FDA批准之前提供正规的retatrutide在医学上是恰当的,这也符合FDA的相关指导原则。该发言人补充道,礼来已建立了一项旨在实现上述目标的“扩大使用计划”,并正在积极评估来自医疗服务提供者的申请。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10